MedTrace Logo

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

NCT02417389 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-04-15

No results posted yet for this study

Summary

To assess the efficacy and safety of treatment with cinacalcet and with cinacalcet plus alendronate in controlling bone loss induced by primary hyperparathyroidism.

Conditions

Interventions

DRUG

cinacalcet

During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).

DRUG

Alendronate

During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).

Sponsors & Collaborators

  • Istituto Auxologico Italiano

    lead OTHER

Principal Investigators

  • Maria Luisa BIANCHI, M.D. · Istituto Auxologico Italiano IRCCS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-10-31
Completion
2012-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02417389 on ClinicalTrials.gov